Thyroid V-50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study

doi:10.1186/s13014-020-01490-x

HFCAS OpenIR

	Thyroid V-50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study
	Zhou, Ling 1,2,3,4; Chen, Jia 5; Shen, Wei 5; Chen, Zheng-Lu 4; Huang, Shuang 1,2,3; Tao, Chang-Juan 1,2,3; Chen, Ming 1,2,3; Yu, Zhong-Hua 6; Chen, Yuan-Yuan 1,2,3
	2020-03-23
发表期刊	RADIATION ONCOLOGY
通讯作者	Yu, Zhong-Hua(zhonghua_yu@126.com) ; Chen, Yuan-Yuan(chenyy@zjcc.org.cn)
摘要	Background We investigated the risk factors of radiation-induced thyroid dysfunction, then combined the clinical factors and optimum thyroid dosimetric parameters to predict the incidence rate of hypothyroidism (HT) and to guide individualized treatment. Methods A total of 206 patients with histologically proven nasopharyngeal carcinoma (NPC) treated at the Cancer Hospital of the University of Chinese Academy of Sciences between January 2015 and August 2018 were included. Dose-volume histogram (DVH) data, including mean dose, absolute volume, V-20, V-25, V-30, V-35, V-40, V-45, V-50,V- V-55, and V-60 were extracted and used as dosimetric parameters. A logistic regression analysis model was built to identify predictors related to HT occurring within 2 years. Results Sex, N stage, thyroid volume, mean thyroid dose, and thyroid V-20 and V-50 were significantly different between patients with and without HT. Logistic regression analysis showed that N stage, thyroid volume, and thyroid V-50 were independent predictors of HT. The radiosensitivity of the thyroid decreased as the thyroid volume increased. Patients with N stage > 1 had significantly higher HT incidence (37.38%) than patients with N stage <= 1 (13.11%). The incidence of HT was 54.55% in patients with thyroid V-50 > 24% and was 34.15% in patients with thyroid V-50 <= 24%. Conclusions The incidence of HT is significantly associated with N stage, thyroid volume, and thyroid V-50. More attention should be paid to patients with NPC with thyroid volume <= 12.82 cm(3) and advanced N stage disease.
关键词	Nasopharyngeal carcinoma Hypothyroidism Radiation therapy
DOI	10.1186/s13014-020-01490-x
关键词[WOS]	QUALITY-OF-LIFE ; NECK-CANCER-PATIENTS ; RADIOTHERAPY ; HEAD
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81672971] ; Key Technologies Research and Development Program[2017YFC0113201]
项目资助者	National Natural Science Foundation of China ; Key Technologies Research and Development Program
WOS研究方向	Oncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Oncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000522186500001
出版者	BMC
引用统计	被引频次：15[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/103602
专题	中国科学院合肥物质科学研究院
通讯作者	Yu, Zhong-Hua; Chen, Yuan-Yuan
作者单位	1.Chinese Acad Sci, ICBM, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Hangzhou, Peoples R China 3.Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China 4.Guangdong Med Univ, Postgrad Educ, Zhanjiang, Peoples R China 5.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China 6.Guangdong Med Univ, Dept Oncol, Affiliated Hosp, Zhanjiang, Peoples R China
推荐引用方式 GB/T 7714	Zhou, Ling,Chen, Jia,Shen, Wei,et al. Thyroid V-50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study[J]. RADIATION ONCOLOGY,2020,15.
APA	Zhou, Ling.,Chen, Jia.,Shen, Wei.,Chen, Zheng-Lu.,Huang, Shuang.,...&Chen, Yuan-Yuan.(2020).Thyroid V-50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study.RADIATION ONCOLOGY,15.
MLA	Zhou, Ling,et al."Thyroid V-50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study".RADIATION ONCOLOGY 15(2020).